Dr Myung-Ju Ahn speaks to ecancer about the evolving role of T-cell engagers in lung cancer.

She discusses the critical balance between maximising efficacy while managing associated toxicities, and outlines key prevention strategies to mitigate adverse effects.

Dr Ahn also explores approaches to patient selection and risk stratification, emphasising the importance of identifying those most likely to benefit from these therapies. She reflects on the future of T-cell engagers, highlighting ongoing challenges and unmet needs in the field.

Additionally, she summarises the key takeaways from the joint European Thoracic Oncology Program (ETOP) and International Breast Cancer Study Group (IBCSG) session, offering a broader perspective on current developments and collaborative efforts in this area.